Estamos no ar no !
Saiba mais
ONCR
Oncorus
Deslistada
ONCR foi retirado da bolsa em 20 de junho de 2023.
Sobre: Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.
Funcionários: 64
Notícias
Positiva
Neutra
Negativa
Sentimento
3 meses
Positiva
0%
Neutra
0%
Negativa
0%
Não recebemos notícias recentes sobre ONCR
Gráficos de preços implementados com Lightweight Charts™